Tamper-resistant OxyContin receives FDA approval

04/5/2010 | Wall Street Journal, The

Purdue Pharma gained FDA approval to market a tamper-resistant formulation of pain drug OxyContin. The agency said the version "will likely result in less abuse by snorting or injection" because its active ingredient turns into a gel when dissolved in liquid, but it can still be abused "by simply ingesting larger doses than are recommended."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA